Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
Jean Ferrières,Michel Farnier,Eric Bruckert,Alexandre Vimont,Vincent Durlach,Emile Ferrari,Antonio Gallo,Franck Boccara,Dorota Ferrières,Sophie Béliard,French FH Registry group: French REgistry of Familial hypERCHOLesterolemia (REFERCHOL),Denis Angoulvant,Karine Aouchiche,Sophie Beliard,Bertrand Cariou,Valérie Carreau,Alain Carrie,Sybil Charrieres,Yves Cottin,Mathilde Di Filippo,Caroline Dourmap,Pierre-Henri Ducluzeau,Dorota Ferrieres,Jean Ferrieres,Regis Hankard,Jocelyn Inamo,Olga Kalmykova,Michel Krempf,Julie Lemale,Philippe Moulin,François Paillard,Noel Peretti,Agnes Perrin,Alain Pradignac,Yann Pucheu,Jean Pierre Rabes,Rachel Reynaud,Vincent Rigalleau,François Schiele,Ariane Sultan,Patrick Tounian,René Valero,Bruno Verges,Cecile Yelnik,Olivier Ziegler
DOI: https://doi.org/10.1016/j.athplu.2022.08.001
2022-08-17
Abstract:Background and aims: Heterozygous familial hypercholesterolemia (HeFH) is increasingly better diagnosed and treatments can improve the cardiovascular prognosis. We evaluated the long-term cardiovascular risk of HeFH using the French REgistry of Familial hypERCHOLesterolemia (REFERCHOL). Methods: We studied HeFH patients diagnosed genetically and clinically by the Dutch Lipid Clinic Network (DLCN) criteria in all lipid clinics across the country and their 5-year risk of cardiovascular events (all fatal and non-fatal acute coronary, cerebral and peripheral arterial disease events, aortic valve replacement surgery) using the French national health data system. Results: The database comprised 3202 individuals, 2010 (62.8%) with genetically verified HeFH and 1192 (37.2%) a DLCN score ≥6. Of these individuals, 2485 (77.6%) were in primary prevention and 717 (22.4%) in secondary prevention. The incidence of cardiovascular events was 24.58 per 1000 person-years for the overall sample, 19.15 in primary prevention and 43.40 in secondary prevention. The incidence of myocardial infarction, cerebral infarction and death was 16.32 per 1000 person-years for the overall sample, 12.93 in primary prevention and 28.08 in secondary prevention. The incidence of aortic valve replacement was 1.78 per 1000 person-years. In the overall sample, at inclusion, 41% were not treated for LDL cholesterol, 48% of these in primary prevention and 20% in secondary prevention and high-dose statins were used by only 24% of individuals, 15% of these in primary prevention and 45% in secondary prevention. Conclusions: The incidence of cardiovascular events in HeFH is high and lipid-lowering treatment is far from optimal. The cardiovascular risk of HeFH is underestimated and patients are inadequately treated.